Immuneering was established based on a shared singular vision: to help people with cancer live longer without compromising quality of life during treatment. That conviction became the foundation of Immuneering. From the beginning, our mission has remained clear and unwavering: develop therapies that improve survival while preserving the quality of life that matters most to patients and their families.
Traditional cancer therapies often aim for rapid tumor shrinkage, an approach that can trigger the tumor to adapt quickly, limiting the duration of clinical benefit. We asked a different question: What if cancer treatment could work with greater endurance and fewer trade-offs for patients?
That question led to Deep Cyclic Inhibitors, a novel therapeutic approach shaped by the biology of resistance. Instead of constant pressure, Deep Cyclic Inhibitors pulses at a frequency designed to stay ahead of tumor adaptation while supporting healthier signaling in normal cells, offering a fundamentally different way to target cancer.
We believe that cancer treatment should not require patients to choose between more time and the ability to live their lives fully. Our Deep Cyclic Inhibition platform is grounded in an approach that unites powerful science with respect for the body. Cinical data from our lead Deep Cyclic Inhibitor, atebimetinib, further reinforces our belief that cancer treatment can be both effective and compatible with maintaining daily function and quality of life during treatment.
Because the MAPK pathway is activated in roughly half of all cancers, Deep Cyclic Inhibitors have relevance across a broad spectrum of tumor types. Our lead Deep Cyclic Inhibitor, atebimetinib, is currently being advanced in pancreatic cancer and lung cancer, with plans to further evaluate its potential in other MAPK-pathway cancers. As momentum builds, we will expand opportunities to bring this approach to more patients who would benefit from improved cancer therapy options.
Our goal isn’t just to improve cancer treatment. It’s to redefine what patients can expect from it. We’re designing therapies to respect the body, enhance quality of life, and enable people to live normal lives and feel like themselves throughout treatment. Ultimately, we aspire to neutralize cancer’s ability to kill, transforming it into a disease that people can live with.
– Ben Zeskind, PhD, Co-founder, President & CEO, Immuneering